Back to MPT Database

Dapivirine + Levonorgestrel IVR

The ring is made of a flexible polymer and contains dapivirine, an ARV, and levonorgestrel, a contraceptive hormone, both of which are slowly released over the course of three months. Women would insert the ring into the vagina themselves and replace it every three months. The Phase 1 bioavailability study will be completed in 2024.

For more information, contact: Stephanie Ecker at secker@popcouncil.org

Development Stage:

Clinical – Phase 1 Trial (C1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Intravaginal - Intravaginal Ring (IVR)

Mechanism of Action:

non-nucleoside analogue reverse transcriptase inhibitor (NNRTI), Progestin

Developer:

  • Population Council

Funding:

  • Ministry of Foreign Affairs of Denmark
  • Nat. Institute Child Health & Human Development (NICHD)
  • The German Federal Ministry of Education and Research (BMBF) through KfW

Funding Mechanism:

(In-kind) US National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Active Ingredient(s):

  • Dapivirine
  • Levonorgestrel

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database